Primary Site >> Pancreatic Cancer
Gene >> AGER
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Differential expression of RAGE in human pancreatic carcinoma cells. PMID: 11813576 |
Ref: Expression of receptor for advanced glycation end products (RAGE) and MMP-9 in human pancreatic cancer cells. PMID: 15239215 |
Ref: Possible participation of advanced glycation end products in the pathogenesis of colorectal cancer in diabetic patients. PMID: 15823719 Ref: S100P promotes pancreatic cancer growth, survival, and invasion. PMID: 16061848 |
Ref: Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. PMID: 17179482 |
Ref: RAGE: a single receptor for several ligands and different cellular responses: the case of certain S100 proteins. PMID: 18331229 |
Ref: The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. PMID: 19834494 Ref: Serum leptin, but not adiponectin and receptor for advanced glycation end products, is able to distinguish autoimmune pancreatitis from both chronic pancreatitis and pancreatic neoplasms. PMID: 19883273 Ref: Soluble receptor for advanced glycation end-products (sRAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer. PMID: 20398646 |
Ref: Apoptosis to autophagy switch triggered by the MHC class III-encoded receptor for advanced glycation endproducts (RAGE). PMID: 20978368 Ref: The Receptor for Advanced Glycation End-products (RAGE) protects pancreatic tumor cells against oxidative injury. PMID: 21126167 Ref: RAGE regulates autophagy and apoptosis following oxidative injury. PMID: 21317562 Ref: Evidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: a prospective study. PMID: 21540233 |
Ref: RAGE gene deletion inhibits the development and progression of ductal neoplasia and prolongs survival in a murine model of pancreatic cancer. PMID: 22052106 Ref: The associations of advanced glycation end products and its soluble receptor with pancreatic cancer risk: a case-control study within the prospective EPIC Cohort. PMID: 22301828 Ref: The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia. PMID: 22509024 Ref: S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis. PMID: 22718861 Ref: AGER/RAGE-mediated autophagy promotes pancreatic tumorigenesis and bioenergetics through the IL6-pSTAT3 pathway. PMID: 22722139 Ref: Autophagy in pancreatic cancer pathogenesis and treatment. PMID: 22860230 |
Ref: Metformin inhibits advanced glycation end products (AGEs)-induced growth and VEGF expression in MCF-7 breast cancer cells by suppressing AGEs receptor expression via AMP-activated protein kinase. PMID: 23225247 Ref: Designing and developing S100P inhibitor 5-methyl cromolyn for pancreatic cancer therapy. PMID: 23303403 Ref: Therapeutic targeting of tumor growth and angiogenesis with a novel anti-S100A4 monoclonal antibody. PMID: 24023743 Ref: Analysis of intercellular signal transduction in the tumor microenvironment. PMID: 24555417 |
Ref: The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics. PMID: 23318458 Ref: S100 family signaling network and related proteins in pancreatic cancer (Review). PMID: 24481067 Ref: RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer. PMID: 25341034 Ref: Determinants of concentrations of N(epsilon)-carboxymethyl-lysine and soluble receptor for advanced glycation end products and their associations with risk of pancreatic cancer. PMID: 25379135 |
Ref: Epidemiological-molecular evidence of metabolic reprogramming on proliferation, autophagy and cell signaling in pancreas cancer. PMID: 24704294 Ref: Novel adjuvants from seaweed impede autophagy signaling in therapy-resistant residual pancreatic cancer. PMID: 25898131 Ref: The receptor for advanced glycation end products (RAGE) enhances autophagy and neutrophil extracellular traps in pancreatic cancer. PMID: 25908451 Ref: The role of S100 proteins and their receptor RAGE in pancreatic cancer. PMID: 26435083 |
Ref: [Effects of RAGE on Cell Proliferation and Tumor Growth in Pancreatic Cancer]. PMID: 28612557 Ref: RAGE maintains high levels of NFkappaB and oncogenic Kras activity in pancreatic cancer. PMID: 28867179 |
Ref: The receptor for advanced glycation end products: A fuel to pancreatic cancer. PMID: 28811077 Ref: RAGE-specific single chain Fv for PET imaging of pancreatic cancer. PMID: 29529089 Ref: The advanced glycation end-product N() -carboxymethyllysine promotes progression of pancreatic cancer: implications for diabetes-associated risk and its prevention. PMID: 29533466 Ref: A prospective study of soluble receptor for advanced glycation end products and adipokines in association with pancreatic cancer in postmenopausal women. PMID: 29573228 Ref: Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps. PMID: 29929491 Ref: The marine natural product Scalarin inhibits the receptor for advanced glycation end products (RAGE) and autophagy in the PANC-1 and MIA PaCa-2 pancreatic cancer cell lines. PMID: 29998364 |